Sommaire

• • ·Table of Contents

    Page :A1

    
• • ·Editorial Board

    Page :A5

    
• • ·Information for Authors

    Page :A6

    
• • ·Information for Readers

    Page :A8

    

• Editorials

  • ·Beyond the numbers: The individual challenges of combating consistently poor survival in heart failure

    Page :195-196

    Simon Stewart

    
  • ·Atrial fibrillation in the setting of acute myocardial infarction —irregularly irregular treatment

    Page :197-199

    Charles L. Campbell, Steven R. Steinhubl

    

• Curriculum in Cardiology

  • ·Epidemiology and risk stratification in acute heart failure

    Page :200-207

    Gregg C. Fonarow

    Résumé Résumé Plan Plan  
  • ·The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing

    Page :208-214

    Alan H.B. Wu, Allan S. Jaffe

    Résumé Résumé Plan Plan  

• Trial Design

  • ·Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial

    Page :215-223

    Michael E. Farkouh, George Dangas, Martin B. Leon, Craig Smith, Richard Nesto, John B. Buse, David J. Cohen, Elizabeth Mahoney, Lynn Sleeper, Spencer King, Michael Domanski, Sonja McKinlay, Valentin Fuster

    Résumé Résumé Plan Plan  
  • ·Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: Rationale and design

    Page :224-230

    Paul S. Myles, Julian Smith, John Knight, D. James Cooper, Brendan Silbert, John McNeil, Donald S. Esmore, Brian Buxton, Henry Krum, Andrew Forbes, Andrew Tonkin, the ATACAS Trial Group

    Résumé Résumé Plan Plan

• Clinical Investigations

  • ·Geometry of the proximal isovelocity surface area in mitral regurgitation by 3-dimensional color Doppler echocardiography: Difference between functional mitral regurgitation and prolapse regurgitation

    Page :231-238

    Yoshiki Matsumura, Shota Fukuda, Hung Tran, Neil L. Greenberg, Deborah A. Agler, Nozomi Wada, Manatomo Toyono, James D. Thomas, Takahiro Shiota

    Résumé Résumé Plan Plan  
  • ·Patients with non–ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy

    Page :239-244

    Derek P. Chew, Zhen Huang, Karen S. Pieper, Harvey White, Kenneth W. Mahaffey, James J. Ferguson, Robert M. Califf, Philip G. Aylward

    Résumé Résumé Plan Plan  
  • ·A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease

    Page :245-253

    Stefano Sdringola, K. Lance Gould, Linda Guilds Zamarka, Richard McLain, Jennifer Garner

    Résumé Résumé Plan Plan  
  • ·Correction

    Page :253

    Hideya Yamamoto

    
  • ·The prevalence of extracardiac findings by multidetector computed tomography before atrial fibrillation ablation

    Page :254-259

    Brian J. Schietinger, Ugur Bozlar, Klaus D. Hagspiel, Patrick T. Norton, Heather R. Greenbaum, Hongkun Wang, David C. Isbell, Rajan A.G. Patel, John D. Ferguson, Spencer B. Gay, Christopher M. Kramer, J. Michael Mangrum

    Résumé Résumé Plan Plan  
  • ·Serious renal dysfunction after percutaneous coronary interventions can be predicted

    Page :260-266

    Jeremiah R. Brown, James T. DeVries, Winthrop D. Piper, John F. Robb, Michael J. Hearne, Peter M. Ver Lee, Mirle A. Kellet, Mathew W. Watkins, Thomas J. Ryan, M. Theodore Silver, Cathy S. Ross, Todd A. MacKenzie, Gerald T. O'Connor, David J. Malenka, for the Northern New England Cardiovascular Disease Study Group

    Résumé Résumé Plan Plan  
  • ·Impact of the New York State Cardiac Surgery and Percutaneous Coronary Intervention Reporting System on the management of patients with acute myocardial infarction complicated by cardiogenic shock

    Page :267-273

    Renato A. Apolito, Mark A. Greenberg, Mark A. Menegus, April M. Lowe, Lynn A. Sleeper, Mark H. Goldberger, Joshua Remick, Martha J. Radford, Judith S. Hochman

    Résumé Résumé Plan Plan
  • ·A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease

    Page :274-283

    Giuseppe G.L. Biondi-Zoccai, Marzia Lotrionte, Claudio Moretti, Emanuele Meliga, Pierfrancesco Agostoni, Marco Valgimigli, Angela Migliorini, David Antoniucci, Didier Carrié, Giuseppe Sangiorgi, Alaide Chieffo, Antonio Colombo, Matthew J. Price, Paul S. Teirstein, Evald H. Christiansen, Antonio Abbate, Luca Testa, Julian P.G. Gunn, Francesco Burzotta, Antonio Laudito, Gian Paolo Trevi, Imad Sheiban

    Résumé Résumé Plan Plan  
  • ·Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus

    Page :284-289

    Avital Porter, Abid R. Assali, Abed Zahalka, Zaza Iakobishvili, David Brosh, Eli I. Lev, Aviv Mager, Alexander Battler, Ran Kornowski, David Hasdai

    Résumé Résumé Plan Plan
  • ·Correction

    Page :289

    David A. Bluemke

    
  • ·Treatment delay in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A key process analysis of patient and program factors

    Page :290-297

    Shailja V. Parikh, Joshua A. Jacobi, Edwin Chu, Tayo A. Addo, John J. Warner, Kathleen A. Delaney, Darren K. McGuire, James A. deLemos, Joaquin E. Cigarroa, Sabina A. Murphy, Ellen C. Keeley

    Résumé Résumé Plan Plan  
  • ·Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) and Aggrastat to Zocor (A to Z) trials

    Page :298-302

    Dalton S. McLean, Shmuel Ravid, Michael Blazing, Bernard Gersh, Amy Shui, Christopher P. Cannon

    Résumé Résumé Plan Plan  
  • ·Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study

    Page :303-309

    Gregory M. Marcus, Mary A. Whooley, David V. Glidden, Ludmila Pawlikowska, Jonathan G. Zaroff, Jeffrey E. Olgin

    Résumé Résumé Plan Plan  
  • ·Atrial fibrillation and obesity—results of a meta-analysis

    Page :310-315

    Nikolas Wanahita, Franz H. Messerli, Sripal Bangalore, Apoor S. Gami, Virend K. Somers, Jonathan S. Steinberg

    Résumé Résumé Plan Plan  
  • ·Class effects of statins in elderly patients with congestive heart failure: A population-based analysis

    Page :316-323

    Stéphane Rinfret, Hassan Behlouli, Mark J. Eisenberg, Karin Humphries, Jack V. Tu, Louise Pilote

    Résumé Résumé Plan Plan  
  • ·Correction

    Page :323

    
  • ·Life expectancy after an index hospitalization for patients with heart failure: A population-based study

    Page :324-331

    Dennis T. Ko, David A. Alter, Peter C. Austin, John J. You, Douglas S. Lee, Feng Qiu, Therese A. Stukel, Jack V. Tu

    Résumé Résumé Plan Plan  
  • ·Heart failure disease management programs: A cost-effectiveness analysis

    Page :332-338

    David C. Chan, Paul A. Heidenreich, Milton C. Weinstein, Gregg C. Fonarow

    Résumé Résumé Plan Plan  
  • ·Characteristics of “Stage D” heart failure: Insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM)

    Page :339-347

    Maria R. Costanzo, Roger M. Mills, Janet Wynne

    Résumé Résumé Plan Plan  
  • ·Lower extremity peripheral arterial disease in individuals with coronary artery disease: Prognostic importance, care gaps, and impact of therapy

    Page :348-355

    Mark J. Makowsky, Finlay A. McAlister, P. Diane Galbraith, Danielle A. Southern, William A. Ghali, Merril L. Knudtson, Ross T. Tsuyuki, for the Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators

    Résumé Résumé Plan Plan  
  • ·Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease

    Page :356-360

    Ada Stefanescu, Siegmund Braun, Gjin Ndrepepa, Tobias Koppara, Herribert Pavaci, Julinda Mehilli, Albert Schömig, Adnan Kastrati

    Résumé Résumé Plan Plan  
  • ·Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry

    Page :361-368

    Tracy Y. Wang, Lee A. Robinson, Fang-Shu Ou, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, Sidney C. Smith, Eric D. Peterson, Richard C. Becker

    Résumé Résumé Plan Plan  
  • ·Association between bleeding, blood transfusion, and costs among patients with non–ST-segment elevation acute coronary syndromes

    Page :369-374

    Sunil V. Rao, Padma R. Kaul, Lawrence Liao, Paul W. Armstrong, E. Magnus Ohman, Christopher B. Granger, Robert M. Califf, Robert A. Harrington, Eric L. Eisenstein, Daniel B. Mark

    Résumé Résumé Plan Plan
  • ·Angina with “normal” coronary arteries: Sex differences in outcomes

    Page :375-381

    Karin H. Humphries, Aihua Pu, Min Gao, Ronald G. Carere, Louise Pilote

    Résumé Résumé Plan Plan  
  • ·Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial

    Page :382-387

    Marco J.D. Tangelder, Lars Frison, Douglas Weaver, Robbert G. Wilcox, Anders Bylock, Håkan Emanuelsson, Peter Held, Jonas Oldgren

    Résumé Résumé Plan Plan  
  • ·Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)–3 trial

    Page :388-394

    Giovanni Pedrazzini, Eugenio Santoro, Roberto Latini, Laurie Fromm, Maria Grazia Franzosi, Tiziano Mocetti, Lidia Staszewsky, Simona Barlera, Gianni Tognoni, Aldo P. Maggioni, for the GISSI-3 Investigators g

    Résumé Résumé Plan Plan  

• Letters to the Editor

  • ·Reply

    Page :e3

    Lizzy M. Brewster, Gert A. van Montfrans, August Sturk

    
  • ·Caveats in determining reference intervals for serum creatine kinase

    Page :e5

    Margherita Capasso, Maria Vittoria De Angelis, Antonio Di Muzio, Antonino Uncini

    
  • ·High-sensitivity C-reactive protein for risk stratification in patients with heart failure

    Page :e7

    Christophe Bauters, Nicolas Lamblin, Pascal de Groote

    
  • ·Relationship of high sensitivity C reactive peptide (hsCRP) to prognosis and other prognostic markers in outpatients with heart failure

    Page :e9

    Jonathan David Windram, Poay Huan Loh, Alan S. Rigby, Andrew L. Clark, John G.F. Cleland

    
  • ·Does lead aVR contain prognostic information in patients with non-ST-elevation acute coronary syndromes?

    Page :e11

    José A. Barrabés, Jaume Figueras

    
  • ·Letter to the Editor

    Page :e13

    Andrew T. Yan, Raymond T. Yan, Shaun G. Goodman

    
  • ·Cardiac defibrillators, Kant, and the categorical imperative

    Page :e15

    Antonio L. Ribeiro, Regina Horta Duarte

    
  • ·Response to “Cardiac defibrillators, Kant, and the categorical imperative” by Ribeiro and Duarte

    Page :e17

    Marc T. Silver